11 news items
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
ALVO
18 Jun 24
deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
ALVO
21 May 24
deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
ALVO
RDY
21 May 24
and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
ALVO
RDY
21 May 24
to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
ALVO
20 May 24
of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (10) the ability of Alvotech
bs866hkl9pdbq6t 6sm1sllcgh
ALVO
TEVA
20 May 24
to inspection findings and resolve deficiencies to the satisfaction of the regulators; (10) the ability of Alvotech or its partners to enroll
0denw 5ehj4fhjgd3tl7lr9
ALVO
TEVA
30 Apr 24
deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10
v2zn2zqpzhll1zdssxfp881vov34vo1hbn3 x1w4nhmstwemg22
ALVO
30 Apr 24
to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability
ej9zir0jbft9qosxebfja0oznsav8oprpzbd7clenbozsckz1t59631gv
ALVO
24 Apr 24
) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9
7bcq25e076u2tptng3f487wq0wlian3726ei31dp2pelyj56sszy1sk
ALVO
TEVA
16 Apr 24
to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll
locstsmnpdw8kiglph23jdyeh12m3uxawnej17o
ALVO
20 Mar 24
findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients
- Prev
- 1
- Next